|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 290 GBX | -1.69% |
|
-7.94% | -17.73% |
| Apr. 02 | MaxCyte inks deal with Be Bio; Orcadian firms farmout | AN |
| Apr. 02 | MaxCyte, Inc. Signs Strategic Platform License with Be Biopharma to Support the Development of Engineered B Cell Medicines | CI |
MaxCyte, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported sales was USD 41.29 million compared to USD 44.26 million a year ago. Net loss was USD 37.92 million compared to USD 23.57 million a year ago.
Basic loss per share from continuing operations was USD 0.37 compared to USD 0.23 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| -17.73% | 384M | |
| +8.07% | 219B | |
| +6.59% | 183B | |
| +11.26% | 133B | |
| +26.57% | 108B | |
| +1.56% | 63.06B | |
| +13.35% | 52.02B | |
| -0.62% | 48.2B | |
| -0.93% | 40.37B | |
| +11.54% | 39.35B |
MAXCYTE, INC. 
